Roche NimbleGen Plans to Debut CNV Arrays for Genome-Wide Association Studies

The products, which are expected to debut early next month, include a 2.1-million feature array and a chip with three 720,000-feature arrays containing CNVs that could be implicated in autism, schizophrenia, autoimmune diseases, and HIV susceptibility.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.